...
search icon
celz-img

Creative Medical Technology Holdings Inc, Common Stock

CELZ

NAQ

$2.05

+$0.09

(4.59%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.20M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
94.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
4.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.92 L
$6.9 H
$2.05

About Creative Medical Technology Holdings Inc, Common Stock

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), which is in phase 2, to treat allogenic human perinatal tissue (Clinical Phase); ImmCelz (CELZ-100), which is in phase 1, a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCELZSectorS&P500
1-Week Return-4.21%-7.84%-11.98%
1-Month Return-46.34%-9.95%-11.4%
3-Month Return-5.53%-4.77%-14.45%
6-Month Return-43.53%-13.28%-13.9%
1-Year Return-63.65%-7.18%-4.3%
3-Year Return-93.69%-5.01%12.94%
5-Year Return-93.17%40.23%78.64%
10-Year Return-99.98%81.1%138.52%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue164.50K87.75K88.60K9.00K11.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":53.35,"profit":true},{"date":"2022-12-31","value":53.86,"profit":true},{"date":"2023-12-31","value":5.47,"profit":true},{"date":"2024-12-31","value":6.69,"profit":true}]
Cost of Revenue50.60K47.95K28.49K3.60K4.40K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.77,"profit":true},{"date":"2022-12-31","value":56.31,"profit":true},{"date":"2023-12-31","value":7.12,"profit":true},{"date":"2024-12-31","value":8.7,"profit":true}]
Gross Profit113.90K39.80K60.11K5.40K6.60K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":34.95,"profit":true},{"date":"2022-12-31","value":52.77,"profit":true},{"date":"2023-12-31","value":4.74,"profit":true},{"date":"2024-12-31","value":5.79,"profit":true}]
Gross Margin69.24%45.36%67.84%60.00%60.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":65.51,"profit":true},{"date":"2022-12-31","value":97.98,"profit":true},{"date":"2023-12-31","value":86.65,"profit":true},{"date":"2024-12-31","value":86.65,"profit":true}]
Operating Expenses1.23M3.17M10.30M5.63M5.75M[{"date":"2020-12-31","value":11.92,"profit":true},{"date":"2021-12-31","value":30.72,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":54.59,"profit":true},{"date":"2024-12-31","value":55.81,"profit":true}]
Operating Income(1.11M)(3.13M)(10.24M)(5.62M)(5.74M)[{"date":"2020-12-31","value":-111483500,"profit":false},{"date":"2021-12-31","value":-312594900,"profit":false},{"date":"2022-12-31","value":-1024437200,"profit":false},{"date":"2023-12-31","value":-562013200,"profit":false},{"date":"2024-12-31","value":-574386100,"profit":false}]
Total Non-Operating Income/Expense(36.44M)18.06M200.66K636.10K500.76K[{"date":"2020-12-31","value":-201.78,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.11,"profit":true},{"date":"2023-12-31","value":3.52,"profit":true},{"date":"2024-12-31","value":2.77,"profit":true}]
Pre-Tax Income(36.33M)19.21M(10.14M)(5.29M)(5.49M)[{"date":"2020-12-31","value":-189.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-52.8,"profit":false},{"date":"2023-12-31","value":-27.52,"profit":false},{"date":"2024-12-31","value":-28.59,"profit":false}]
Income Taxes1.23M4.28M(100.33K)(4.00)-[{"date":"2020-12-31","value":28.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.34,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(37.55M)14.93M(10.04M)(5.29M)-[{"date":"2020-12-31","value":-251.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-67.26,"profit":false},{"date":"2023-12-31","value":-35.4,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(36.33M)19.21M(10.14M)(9.82M)(5.49M)[{"date":"2020-12-31","value":-189.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-52.8,"profit":false},{"date":"2023-12-31","value":-51.13,"profit":false},{"date":"2024-12-31","value":-28.59,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(37.55M)14.93M(10.04M)(5.29M)(5.49M)[{"date":"2020-12-31","value":-251.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-67.26,"profit":false},{"date":"2023-12-31","value":-35.4,"profit":false},{"date":"2024-12-31","value":-36.79,"profit":false}]
EPS (Diluted)(37.08)5.02(0.52)(3.06)(3.71)[{"date":"2020-12-31","value":-738.66,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-10.36,"profit":false},{"date":"2023-12-31","value":-60.96,"profit":false},{"date":"2024-12-31","value":-73.9,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CELZ
Cash Ratio 18.13
Current Ratio 18.73
Quick Ratio 18.72

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CELZ
ROA (LTM) -41.30%
ROE (LTM) -65.85%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CELZ
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CELZ
Trailing PE NM
Forward PE NM
P/S (TTM) 472.60
P/B 0.79
Price/FCF NM
EV/R 56.07
EV/Ebitda NM

FAQs

What is Creative Medical Technology Holdings Inc share price today?

Creative Medical Technology Holdings Inc (CELZ) share price today is $2.05

Can Indians buy Creative Medical Technology Holdings Inc shares?

Yes, Indians can buy shares of Creative Medical Technology Holdings Inc (CELZ) on Vested. To buy Creative Medical Technology Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CELZ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Creative Medical Technology Holdings Inc be purchased?

Yes, you can purchase fractional shares of Creative Medical Technology Holdings Inc (CELZ) via the Vested app. You can start investing in Creative Medical Technology Holdings Inc (CELZ) with a minimum investment of $1.

How to invest in Creative Medical Technology Holdings Inc shares from India?

You can invest in shares of Creative Medical Technology Holdings Inc (CELZ) via Vested in three simple steps:

  • Click on Sign Up or Invest in CELZ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Creative Medical Technology Holdings Inc shares
What is Creative Medical Technology Holdings Inc 52-week high and low stock price?

The 52-week high price of Creative Medical Technology Holdings Inc (CELZ) is $6.9. The 52-week low price of Creative Medical Technology Holdings Inc (CELZ) is $1.92.

What is Creative Medical Technology Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Creative Medical Technology Holdings Inc (CELZ) is 0.79

What is the Market Cap of Creative Medical Technology Holdings Inc?

The market capitalization of Creative Medical Technology Holdings Inc (CELZ) is $5.20M

What is Creative Medical Technology Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Creative Medical Technology Holdings Inc is CELZ

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top